

Myanmar

Support for Vaccine: Japanese Encephalitis Vaccine This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Myanmar						
2. Vaccine grant number:	17-MMR-08i-Y, 18-MMR-26b-X, 1921-MMR-26b-X						
3. Date of Decision Letter:	30 September 2019						
4. Date of the Partnership Framework Agreement:	4 April 2014						
5. Programme title:	New Vaccine Support (NVS), Japanese Encephalitis, Routine						
6. Vaccine type:	Japanese Encephalitis						
7. Requested product presentation and formulation of vaccine:	Japanese Encephalitis, 5 dose(s) per vial, LYOPHILISED						
8. Programme Duration:¹	2018-2021						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement)						
	2018-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	903,000	-	387,500	-	-	-	1,290,500
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number					Amount (US\$)
	2017	17-MMR-08i-Y					852,000
	Disbursement						
	Disbursement date						Amount (US\$)
	01 June, 2017						421,320
	25 April, 2017						430,680
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement)						
	Type of supplies to be purchased with Gavi funds	2018-2019	2020				2021

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

	Number of vaccine doses		-	-
	Annual Amounts (US\$)	903,000	-	-
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
14. Self-procurement:	Not applicable			
15. Co-financing obligations:	According to the co-financing policy, the Country falls within the group: Preparatory transition phase			
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.				
Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023
Number of vaccine doses	-	114,500	-	-
Number of AD syringes	-	113,400	-	-
Number of re-constitution syringes	-	25,200	-	-
Number of safety boxes	-	1,550	-	-
Value of vaccine doses (US\$)	-	50,343	-	-
Total co-financing payments (US\$) (including freight)	-	57,000	-	-
16. Operational support for campaigns:	Not applicable			
17. Additional Reporting Requirements:				
	Due dates			
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:				
<ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; 	31 March 2020			
<ul style="list-style-type: none"> number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. 	15 May 2020			
<ul style="list-style-type: none"> Countries shall report the actual switch date in the first renewal request following the actual implementation. 	N/A			
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat			

18. Financial clarifications:	Country shall provide the following clarifications to Gavi*:
Not applicable	
* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.	
19. Other conditions:	
Not applicable	

Signed by,

On behalf of Gavi



Thabani Maphosa
Managing Director, Country Programmes
30 September 2019